AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12411535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12411535 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham halothane with AOX
Number of subjects: 16
Study 12411535 — intervention group
Group type: COMPARATOR
Intervention: Sham halothane with placebo
Number of subjects: 16
Study 10445218 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron plus zinc supplementation (12 mg/day of Fe+++ and 12.5 mg/day of Zn++)
Number of subjects: 30
Study 10445218 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (12.5 mg/day of Zn++)
Number of subjects: 30
Study 10445218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8575690 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagifem (25 micrograms oestradiol) administered as vaginal pessaries daily, 3 weeks prior to surgery
Number of subjects: 43
Study 8575690 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered as vaginal pessaries daily, 3 weeks prior to surgery
Number of subjects: 43
Study 8575690 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oestradiol group
Number of subjects: 43
Study 8575690 — intervention group
Group type: COMPARATOR
Intervention: Preoperative placebo group
Number of subjects: 43
Study 8575690 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oestradiol treatment
Number of subjects: 43
Study 8575690 — intervention group
Group type: COMPARATOR
Intervention: Preoperative placebo treatment
Number of subjects: 43
Study 1976665 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (H1-receptor antagonist)
Number of subjects: 0
Study 1976665 — intervention group
Group type: COMPARATOR
Intervention: Control (Histamine provocation challenge)
Number of subjects: 0
Study 6761851 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS)
Number of subjects: 75
Study 6761851 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 75
Study 30663195 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD‐EPIeGFR
Number of subjects: 17762
Study 30663195 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS1eGFR
Number of subjects: 17762
Study 28740213 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanyl-Glutamine (AlaGln) supplementation in PD fluid
Number of subjects: 6
Study 28740213 — intervention group
Group type: COMPARATOR
Intervention: Standard PD fluid (Control)
Number of subjects: 6
Study 26277381 — intervention group
Group type: EXPERIMENTAL
Intervention: Total saturated fatty acids, palmitoleic acid (16:1n-7), dihomo-γ-linolenic acid (20:3n-6), estimated stearoyl-CoA desaturase 1 and Δ6-desaturase (D6D) enzyme activities
Number of subjects: 1302
Study 26277381 — intervention group
Group type: EXPERIMENTAL
Intervention: Total polyunsaturated fatty acid, linoleic acid (18:2n-6), elongase activity
Number of subjects: 1302
Study 26277381 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated D6D activity, dihomo-γ-linolenic acid (20:3n-6)
Number of subjects: 1302
Study 24865945 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure (AA) treatment for 8 weeks
Number of subjects: 60
Study 24865945 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study 21623963 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10mg)
Number of subjects: 178
Study 21623963 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40mg)
Number of subjects: 178
Study 21623963 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10mg) plus Simvastatin (40mg)
Number of subjects: 178
Study 21623963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 19042945 — intervention group
Group type: EXPERIMENTAL
Intervention: Feces stored at 4 degrees C for 3 days
Number of subjects: 0
Study 19042945 — intervention group
Group type: EXPERIMENTAL
Intervention: Feces stored at 37 degrees C for 72 hours
Number of subjects: 0
Study 19042945 — intervention group
Group type: COMPARATOR
Intervention: Feces stored at 37 degrees C for any time
Number of subjects: 0
Study 19358184 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy (intravenous for 24 hours, followed by oral for 10 days)
Number of subjects: 369
Study 19358184 — intervention group
Group type: COMPARATOR
Intervention: Appendicectomy (surgery)
Number of subjects: 369
Study 19358184 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 369
Study 19358184 — intervention group
Group type: COMPARATOR
Intervention: Appendicectomy
Number of subjects: 369
Study 15718406 — intervention group
Group type: EXPERIMENTAL
Intervention: New Fourier-based approach to analyze blood pressure variability
Number of subjects: 0
Study 15718406 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods to compute blood pressure variability
Number of subjects: 0
Study 12088166 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute treatment
Number of subjects: 50
Study 12088166 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute and maintenance treatment
Number of subjects: 50
Study 12088166 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatment
Number of subjects: 50
Study 9643406 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal balloon endometrial ablation for 8-16 minutes
Number of subjects: 8
Study 8187941 — intervention group
Group type: EXPERIMENTAL
Intervention: azelastine nasal spray 0.14 mg/nostril twice daily (0.56 mg/day)
Number of subjects: 40
Study 8187941 — intervention group
Group type: COMPARATOR
Intervention: cetirizine tablets 10 mg once daily
Number of subjects: 40
Study 8187941 — intervention group
Group type: EXPERIMENTAL
Intervention: azelastine nasal spray
Number of subjects: 40
Study 2432009 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 21
Study 2432009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 12068264 — intervention group
Group type: EXPERIMENTAL
Intervention: Bibliotherapy/drinking guidelines (n = 411); participants received two pamphlets with information about the effects of alcohol and guidelines for low-risk drinking and self-monitoring.
Number of subjects: 825
Study 12068264 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement/personalized feedback (n = 414); participants received personalized advice/feedback based on their assessment of drinking and related behaviors.
Number of subjects: 825
Study 12068264 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (combined);
Number of subjects: 825
Study 30507549 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue oxygenation
Number of subjects: 0
Study 30507549 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot care knowledge and practice for patients with diabetes mellitus
Number of subjects: 0
Study 27849166 — intervention group
Group type: EXPERIMENTAL
Intervention: FR104 (0.02 mg/kg to 1.500 mg/kg)
Number of subjects: 64
Study 27849166 — intervention group
Group type: EXPERIMENTAL
Intervention: FR104
Number of subjects: 64
Study 25061688 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse telehealth coaching for five sessions
Number of subjects: 101
Study 25061688 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 101
Study 22726372 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer levels at admission in patients with severe CAP
Number of subjects: 147
Study 22726372 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer levels at admission in patients with clinical failure at day 30
Number of subjects: 147
Study 22726372 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer levels at admission in patients with early failure
Number of subjects: 147
Study 22726372 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer levels in non-survivors
Number of subjects: 147
Study 22726372 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer levels <500 μg/l
Number of subjects: 147
Study 22726372 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer levels as a predictor for clinical outcome at day 30
Number of subjects: 147
Study 22726372 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer levels as a predictor for 30-day mortality
Number of subjects: 147
Study 22726372 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of D-dimer levels to CURB-65
Number of subjects: 147
Study 22726372 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial D-dimer levels between patients with clinical success or failure at day 30
Number of subjects: 147
Study 21098580 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily remote device monitoring (electrocardiogram, blood pressure, body weight) coupled with medical telephone support
Number of subjects: 710
Study 21098580 — intervention group
Group type: COMPARATOR
Intervention: Usual care led by the patients' local physician
Number of subjects: 710
Study 21098580 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily remote device monitoring
Number of subjects: 710
Study 21098580 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 710
Study 18248490 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg q.d.)
Number of subjects: 306
Study 18248490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 16351673 — intervention group
Group type: EXPERIMENTAL
Intervention: Single steroid injection (methylprednisolone acetate) plus saline injection at 8 weeks
Number of subjects: 40
Study 16351673 — intervention group
Group type: COMPARATOR
Intervention: Double steroid injections (methylprednisolone acetate) at baseline and at 8 weeks
Number of subjects: 40
Study 16351673 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (single and double injections)
Number of subjects: 40
Study 11979570 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated procedure for longitudinal measurement of tissue volume and relaxation times
Number of subjects: 5
Study 11979570 — intervention group
Group type: COMPARATOR
Intervention: Manual segmentation by two radiologists
Number of subjects: 5
Study 11979570 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative MR imaging measures
Number of subjects: 5
Study 10505589 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 16
Study 10505589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7574001 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% cocaine
Number of subjects: 0
Study 7574001 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine in oxymetazoline
Number of subjects: 0
Study 7574001 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% tetracaine in oxymetazoline
Number of subjects: 0
Study 7574001 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 1752116 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human superoxide dismutase (rhSOD)
Number of subjects: 32
Study 7034861 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous wart vaccine
Number of subjects: 34
Study 7034861 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaccine
Number of subjects: 34
Study 31888122 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose hydrogen breath test (H2BT)
Number of subjects: 253
Study 31888122 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose hydrogen breath test (H2BT)
Number of subjects: 253
Study 31888122 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic elimination diet
Number of subjects: 253
Study 31888122 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate malabsorption diagnosis
Number of subjects: 253
Study 28356068 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 46
Study 28356068 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (deflated cuff)
Number of subjects: 46
Study 26921645 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Pudendal Nerve Stimulation (EPNS)
Number of subjects: 42
Study 26921645 — intervention group
Group type: COMPARATOR
Intervention: Electromyogram biofeedback (BF)‐assisted pelvic floor muscle training (PFMT) plus transvaginal electrical stimulation (TES)
Number of subjects: 42
Study 24442926 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM2028-benzydamine
Number of subjects: 38
Study 24442926 — intervention group
Group type: COMPARATOR
Intervention: CAM2028-control
Number of subjects: 38
Study 22845633 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact isolation application
Number of subjects: 117
Study 22845633 — intervention group
Group type: COMPARATOR
Intervention: Non-isolated patients
Number of subjects: 117
Study 20859673 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary acrylamide intake (highest quintile)
Number of subjects: 27111
Study 20859673 — intervention group
Group type: COMPARATOR
Intervention: Dietary acrylamide intake (lowest quintile)
Number of subjects: 27111
Study 17437877 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA
Number of subjects: 100
Study 17437877 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA + 2.5% NaOCl
Number of subjects: 100
Study 17437877 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatments (treatment solution with subsequent NaOCl application)
Number of subjects: 100
Study 17437877 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EGTA + 2.5% NaOCl
Number of subjects: 100
Study 17437877 — intervention group
Group type: EXPERIMENTAL
Intervention: Single treatments
Number of subjects: 100
Study 17437877 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment time of 5 minutes
Number of subjects: 100
Study 15756615 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL reconstruction using the central third of the patellar tendon
Number of subjects: 10
Study 15756615 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 10
Study 11506819 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (30 mg per day)
Number of subjects: 30
Study 11506819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9743394 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg sufentanil plus 30 microg clonidine
Number of subjects: 53
Study 9743394 — intervention group
Group type: COMPARATOR
Intervention: 5 microg sufentanil
Number of subjects: 53
Study 8064101 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive training
Number of subjects: 110
Study 8064101 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined resistive/balance training
Number of subjects: 110
Study 8064101 — intervention group
Group type: COMPARATOR
Intervention: Balance training
Number of subjects: 110
Study 8064101 — intervention group
Group type: COMPARATOR
Intervention: Control group (health-related discussion sessions)
Number of subjects: 110
Study 2538094 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-chloroprocaine with 8.4% sodium bicarbonate
Number of subjects: 62
Study 2538094 — intervention group
Group type: COMPARATOR
Intervention: 2-chloroprocaine with normal saline (control)
Number of subjects: 62
Study 2538094 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent bupivacaine analgesia
Number of subjects: 62
Study 2538094 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine dosage during first stage of labor
Number of subjects: 62
Study 2538094 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain scores over time
Number of subjects: 62
Study 31028957 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (35 mg weekly)
Number of subjects: 258
Study 31028957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study 28011288 — intervention group
Group type: EXPERIMENTAL
Intervention: NOMAC/E2 (2.5 mg/1.5 mg) in a 24/4-day regimen
Number of subjects: 4317
Study 28011288 — intervention group
Group type: COMPARATOR
Intervention: DRSP/EE (3 mg/30 μg) in a 21/7-day regimen
Number of subjects: 4317
Study 28011288 — intervention group
Group type: EXPERIMENTAL
Intervention: NOMAC/E2
Number of subjects: 4317
Study 28011288 — intervention group
Group type: COMPARATOR
Intervention: DRSP/EE
Number of subjects: 4317
Study 25066875 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate capsule sparing cystectomy
Number of subjects: 40
Study 25066875 — intervention group
Group type: COMPARATOR
Intervention: Nerve sparing cystectomy
Number of subjects: 40
Study 23365126 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding (BRF)
Number of subjects: 48
Study 23365126 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-feeding (FOF)
Number of subjects: 48
Study 21980799 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with a high-dose 6-grass pollen preparation
Number of subjects: 46
Study 19262499 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt substitute (65% sodium chloride, 25% potassium chloride, 10% magnesium sulfate)
Number of subjects: 600
Study 19262499 — intervention group
Group type: COMPARATOR
Intervention: Regular salt (100% sodium chloride)
Number of subjects: 600
Study 17924020 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluor protector every six months (experimental group A, n=207, 335 teeth)
Number of subjects: 622
Study 17924020 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass-ionomer cement as pit and fissure sealant (experimental group B, n=205, 327 teeth)
Number of subjects: 622
Study 17924020 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group, n=210, 354 teeth)
Number of subjects: 622
Study 15065832 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron lung ventilation (ILV)
Number of subjects: 44
Study 15065832 — intervention group
Group type: COMPARATOR
Intervention: Invasive mechanical ventilation (IMV)
Number of subjects: 44
Study 10702458 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion (100 microg. kg(‐1). min(‐1))
Number of subjects: 60
Study 10702458 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (1.0%, end‐tidal) with nitrous oxide 66%
Number of subjects: 60
Study 8922197 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD/Bio (cisplatin, vinblastine, DTIC followed by IL-2 and IFN-alpha)
Number of subjects: 102
Study 8922197 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio/CVD (IL-2 and IFN-alpha followed by cisplatin, vinblastine, DTIC)
Number of subjects: 102
Study 8922197 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential biochemotherapy (CVD followed by IL-2 and IFN-alpha)
Number of subjects: 102
Study 8922197 — intervention group
Group type: COMPARATOR
Intervention: CVD (cisplatin, vinblastine, DTIC alone)
Number of subjects: 102
Study 8922197 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD/Bio
Number of subjects: 102
Study 2861876 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine 1.5 g/day
Number of subjects: 60
Study 2861876 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine 3 g/day
Number of subjects: 60
Study 2861876 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine > 40 mg/kg/day
Number of subjects: 60
Study 2861876 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of sulphasalazine and its metabolites
Number of subjects: 60
Study 30292919 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin tests (prick and intradermal tests) for taxanes
Number of subjects: 84
Study 30292919 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded challenge
Number of subjects: 84
Study 30292919 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitization schedule
Number of subjects: 84
Study 30292919 — intervention group
Group type: COMPARATOR
Intervention: Skin tests in control group
Number of subjects: 84
Study 28326925 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum electroacupuncture (ipsilateral)
Number of subjects: 24
Study 28326925 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum electroacupuncture (contralateral)
Number of subjects: 24
Study 28326925 — intervention group
Group type: COMPARATOR
Intervention: Placebo electroacupuncture (ipsilateral)
Number of subjects: 24
Study 28326925 — intervention group
Group type: COMPARATOR
Intervention: Placebo electroacupuncture (contralateral)
Number of subjects: 24
Study 26009799 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT; 100 μg) introduced in a single dose after three hours from the beginning of TK analgesia (TKF treatment)
Number of subjects: 0
Study 26009799 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac (0.86 mg/kg/day) and tramadol (7.2 mg/kg/day) (TK treatment)
Number of subjects: 0
Study 26009799 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT; 100 μg)
Number of subjects: 0
Study 24369953 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening (two-view film-screen mammography)
Number of subjects: 86276
Study 24369953 — intervention group
Group type: COMPARATOR
Intervention: Review of interval cancers by offsite radiologists
Number of subjects: 86276
Study 22672794 — intervention group
Group type: EXPERIMENTAL
Intervention: I-ONE therapy (PEMFs) for 4 hours/day for 60 days
Number of subjects: 30
Study 22672794 — intervention group
Group type: EXPERIMENTAL
Intervention: I-ONE therapy (PEMFs)
Number of subjects: 30
Study 22672794 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard rehabilitation)
Number of subjects: 30
Study 19572829 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive TDT (aTDT)
Number of subjects: 0
Study 19572829 — intervention group
Group type: COMPARATOR
Intervention: MAX test
Number of subjects: 0
Study 19572829 — intervention group
Group type: COMPARATOR
Intervention: CLRT
Number of subjects: 0
Study 19572829 — intervention group
Group type: COMPARATOR
Intervention: Optimal TDT-type test
Number of subjects: 0
Study 17300600 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 ms pulse width
Number of subjects: 19
Study 17300600 — intervention group
Group type: COMPARATOR
Intervention: 40 ms pulse width
Number of subjects: 19
Study 17300600 — intervention group
Group type: EXPERIMENTAL
Intervention: Both pulse widths (0.45 ms and 40 ms)
Number of subjects: 19
Study 17300600 — intervention group
Group type: EXPERIMENTAL
Intervention: Both pulse widths
Number of subjects: 19
Study 15013307 — intervention group
Group type: EXPERIMENTAL
Intervention: MM-Cept 500 mg tablets
Number of subjects: 0
Study 15013307 — intervention group
Group type: COMPARATOR
Intervention: Cellcept 500 mg tablets
Number of subjects: 0
Study 12888152 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 0
Study 12888152 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0